IBI 3030
Alternative Names: IBI-3030Latest Information Update: 08 Nov 2025
At a glance
- Originator Innovent Biologics
- Class Antibodies; Antihyperglycaemics; Obesity therapies; Peptide drug conjugates
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 21 Jun 2025 Pharmacodynamics and adverse events data from preclinical trial in Metabolic disorders released by Innovent Biologics
- 20 Jun 2025 Pharmacodynamic data from a preclinical trial in Metabolic disorders presented at 85th Annual Scientific Sessions of the American Diabetes Association (ADA 2025)
- 12 Jun 2025 Preclinical trials in Metabolic disorders in China (unspecified route), before June 2025